Matching articles for "doxorubicin"
Issue 1713 · October 14, 2024 Free
In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)

Afamitresgene autoleucel ( Tecelra – Adaptimmune), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, has received accelerated approval from the FDA for…

Med Lett Drugs Ther. 2024 Oct 14; 66(1713):e169-70 doi:10.58347/tml.2024.1713i
Afamitresgene autoleucel ( Tecelra – Adaptimmune), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen. It is the first gene therapy to be approved in the US for treatment of synovial sarcoma. Accelerated approval of the immunotherapy was based on the overall response rate and duration of response.
Issue 1682 · August 7, 2023
Glofitamab (Columvi) for Diffuse Large B-Cell Lymphoma (online only)

Glofitamab-gxbm ( Columvi – Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for IV treatment of relapsed or refractory diffuse large B-cell lymphoma…

Med Lett Drugs Ther. 2023 Aug 7; 65(1682):e129-30 doi:10.58347/tml.2023.1682b
Glofitamab-gxbm ( Columvi – Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for IV treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or large B-cell lymphoma (LBCL) arising from follicular lymphoma after ≥2 lines of systemic therapy. Accelerated approval was based on response rates and durability of response. Glofitamab is the second T-cell-engaging bispecific antibody to be approved in the US for treatment of DLBCL; epcoritamab-bysp (Epkinly) , which is given subcutaneously, was approved earlier. Unlike epcoritamab, glofitamab is not approved for treatment of high-grade B-cell lymphoma.
Issue 1679 · June 26, 2023 Free
In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)

The FDA has approved lisocabtagene maraleucel ( Breyanzi – BMS) for treatment of adults with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade…

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):e104-5 doi:10.58347/tml.2023.1679f
The FDA has approved lisocabtagene maraleucel ( Breyanzi – BMS) for treatment of adults with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, or follicular lymphoma grade 3B who have disease refractory to first-line chemoimmunotherapy, relapsed within 12 months of or after first-line chemoimmunotherapy, are not eligible for hematopoietic stem cell transplantation due to comorbidities or age, or have relapsed or refractory disease after ≥2 lines of systemic therapy. Breyanzi is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. The CAR T-cell products axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) are also FDA-approved for treatment of large B-cell lymphoma.
Issue 1678 · June 12, 2023
Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)

Epcoritamab-bysp ( Epkinly – Genmab), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for subcutaneous treatment of relapsed or refractory diffuse large B-cell…

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):e103-4 doi:10.58347/tml.2023.1678d
Epcoritamab-bysp ( Epkinly – Genmab), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for subcutaneous treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥2 lines of systemic therapy. Epcoritamab is the second T-cell-engaging bispecific antibody to become available in the US for treatment of non-Hodgkin's lymphoma; mosunetuzumab-axgb (Lunsumio) was recently approved for relapsed or refractory follicular lymphoma, a common subtype of non-Hodgkin's lymphoma.
Issue 1677 · May 29, 2023
Polatuzumab vedotin (Polivy) for Lymphoma (online only)

Polatuzumab vedotin-piiq ( Polivy – Genentech), a CD79b-directed antibody and microtubule inhibitor conjugate, has been approved by the FDA for use in combination with rituximab, cyclophosphamide,…

Med Lett Drugs Ther. 2023 May 29; 65(1677):e89-90 doi:10.58347/tml.2023.1677f
Polatuzumab vedotin-piiq ( Polivy – Genentech), a CD79b-directed antibody and microtubule inhibitor conjugate, has been approved by the FDA for use in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for first-line treatment of diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) in adults who have an International Prognostic Index (IPI) score ≥2. The drug was previously approved for use in combination with bendamustine and rituximab for treatment of patients with relapsed or refactory DLBCL, NOS, who received at least 2 prior therapies.
Issue 1663 · November 14, 2022
A New Indication for Axicabtagene Ciloleucel (Yescarta) (online only)

The FDA recently approved axicabtagene ciloleucel ( Yescarta – Kite), a CD19-directed genetically modified cellular product, for treatment of large B-cell lymphoma that is refractory to first-line…

Med Lett Drugs Ther. 2022 Nov 14; 64(1663):e194-5
The FDA recently approved axicabtagene ciloleucel ( Yescarta – Kite), a CD19-directed genetically modified cellular product, for treatment of large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line treatment. It was previously approved for treatment of relapsed or refractory B-cell lymphoma after ≥2 lines of systemic therapy and for treatment of relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient.
Issue 1617 · February 8, 2021
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)

The FDA has approved sacituzumab govitecan-hziy ( Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with…

Med Lett Drugs Ther. 2021 Feb 8; 63(1617):e24-5
The FDA has approved sacituzumab govitecan-hziy ( Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with metastatic triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Issue 1559 · November 5, 2018 Free
In Brief: Brentuximab Vedotin (Adcetris) for Classical Hodgkin's Lymphoma (online only)

The FDA has approved the anti-CD30 antibody-drug conjugate brentuximab vedotin ( Adcetris – Seattle Genetics) for use in combination with chemotherapy for IV treatment of adults with previously untreated…

Med Lett Drugs Ther. 2018 Nov 5; 60(1559):e185
The FDA has approved the anti-CD30 antibody-drug conjugate brentuximab vedotin ( Adcetris – Seattle Genetics) for use in combination with chemotherapy for IV treatment of adults with previously untreated stage 3 or 4 classical Hodgkin's lymphoma (cHL). Adcetris was approved earlier for consolidation treatment of cHL and for treatment of relapsed or refractory cHL, anaplastic large cell lymphoma, and CD30-expressing mycosis fungoides. FDA approval for the new indication was based on the results of an open-label trial (ECHELON-1) in 1334 patients with previously untreated stage 3 or 4 cHL. 1 Patients were randomized to receive a regimen consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD; standard initial treatment for cHL) or a regimen that included brentuximab vedotin instead of bleomycin (A+AVD). Bleomycin can cause severe pulmonary toxicity and is often dropped from the regimen after several cycles of ABVD. The 2-year modified progression-free survival rate (the primary endpoint; defined as time to progression, death, or noncomplete response and use of subsequent anticancer therapy) was 82.1% with A+AVD and 77.2% with ABVD, a statistically significant difference. Neutropenia and peripheral neuropathy were more common with A+AVD than with ABVD (58% vs 45% and 67% vs 43%, respectively). Severe pulmonary toxicity was more common with ABVD (3% vs <1%). Of the 9 deaths that occurred in the A+AVD group, 7 were related to neutropenia; 11 of the 13 deaths in the ABVD group were related to pulmonary toxicity. PET scans to evaluate the response to therapy, which could have permitted discontinuation of bleomycin after the first 2 cycles and decreased the risk of pulmonary toxicity, were not performed. 2 Six cycles of A+AVD have been estimated to cost up to $850,000, compared to less than $8000 for ABVD. 3 There is no evidence to date that the new regimen improves overall survival in patients with previously untreated stage 3 or 4 cHL. JM Connors et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med 2018; 378:331. T Hilal. Brentuximab vedotin for stage III or IV Hodgkin's lymphoma. N Engl J Med 2018; 378:1558. JP Greer. Brentuximab vedotin for stage III or IV Hodgkin's lymphoma. N Eng J Med 2018; 378:1559. Download complete U.S. English article
Issue 1551 · July 16, 2018
Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)

The FDA has approved axicabtagene ciloleucel ( Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy. Yescarta is an…

Med Lett Drugs Ther. 2018 Jul 16; 60(1551):e122-3
The FDA has approved axicabtagene ciloleucel ( Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. It is the second CAR T-cell immunotherapy to become available in the US. Tisagenlecleucel (Kymriah ), a CAR T-cell product previously approved for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients ≤25 years old, was recently also approved for relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy.
Issue 1527 · August 14, 2017
Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)

Olaratumab (Lartruvo – Lilly), a platelet-derived growth factor receptor alpha (PDGFR-α) blocking monoclonal antibody, has received accelerated approval from the FDA for use in combination with the…

Med Lett Drugs Ther. 2017 Aug 14; 59(1527):e138-9
Olaratumab (Lartruvo – Lilly), a platelet-derived growth factor receptor alpha (PDGFR-α) blocking monoclonal antibody, has received accelerated approval from the FDA for use in combination with the anthracycline doxorubicin for first-line treatment of adults with soft-tissue sarcoma histologic subtypes considered susceptible to anthracyclines. Approval is limited to locally advanced or metastatic soft-tissue sarcomas that are not amenable to curative radiotherapy or surgery, and is contingent on verification of clinical benefit in a confirmatory phase 3 trial.
Issue 1475 · August 17, 2015
Lenvatinib (Lenvima) for Thyroid Cancer (online only)

The FDA has approved the oral multikinase inhibitor lenvatinib ( Lenvima – Eisai) for treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer (papillary or follicular)…

Med Lett Drugs Ther. 2015 Aug 17; 57(1475):e120-1
The FDA has approved the oral multikinase inhibitor lenvatinib ( Lenvima – Eisai) for treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer (papillary or follicular) refractory to radioactive iodine treatment.
Issue 1467 · April 27, 2015
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting

The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK 1 ) receptor antagonist netupitant and the serotonin-3 (5-HT 3 ) receptor antagonist…

Med Lett Drugs Ther. 2015 Apr 27; 57(1467):61-3
The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK 1 ) receptor antagonist netupitant and the serotonin-3 (5-HT 3 ) receptor antagonist palonosetron, for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy in adults. Akynzeo is the first product to combine drugs from these two classes. Palonosetron (Aloxi) is also available as a single agent for prevention of chemotherapy-induced and postoperative nausea and vomiting. Netupitant is the second substance P/NK 1 receptor antagonist to be approved in the US; aprepitant (Emend) was the first.
Issue 1333 · March 8, 2010
Hyperbaric Oxygen Therapy for Refractory Wounds

Hyperbaric oxygen (HBO 2 ) therapy, breathing 100% O 2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic foot ulcers.

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):19-20
Hyperbaric oxygen (HBO 2 ) therapy, breathing 100% O 2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic foot ulcers.
Issue 1287 · June 2, 2008
Bevacizumab (Avastin) for Metastatic Breast Cancer

Bevacizumab ( Avastin - Genentech) is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor and prevents it from binding to receptors on endothelial cells, inhibiting…

Med Lett Drugs Ther. 2008 Jun 2; 50(1287):42-3
Bevacizumab ( Avastin - Genentech) is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor and prevents it from binding to receptors on endothelial cells, inhibiting formation of new blood vessels. Previously approved by the FDA for use in combination regimens for first-line treatment of metastatic colon cancer and metastatic non-small cell lung cancer, and used off-label for treatment of agerelated macular degeneration, it has now also been approved by the FDA for use in combination with paclitaxel ( Taxol , and others) for first-line treatment of HER2-negative metastatic breast cancer.
Issue 1278 · January 28, 2008
Ixabepilone (Ixempra) for Breast Cancer

Ixabepilone (ix ab ep' i lone; Ixempra - Bristol-Myers Squibb), a semisynthetic epothilone analog, has been approved by the FDA for treatment of advanced breast cancer. It is indicated for use in combination…

Med Lett Drugs Ther. 2008 Jan 28; 50(1278):7-8
Ixabepilone (ix ab ep' i lone; Ixempra - Bristol-Myers Squibb), a semisynthetic epothilone analog, has been approved by the FDA for treatment of advanced breast cancer. It is indicated for use in combination with capecitabine ( Xeloda - Roche) for treatment of locally advanced or metastatic breast cancer after failure of an anthracycline such as doxorubicin ( Adriamycin ) and a taxane such as paclitaxel ( Taxol , and others). It is also approved as monotherapy for treatment of metastatic or locally advanced breast cancer after an anthracycline, a taxane and capecitabine have failed.
Issue 1275 · December 3, 2007 Free
In Brief: Dexrazoxane for Anthracycline Extravasation

The FDA has approved a new formulation of dexrazoxane (Totect) for treatment of extravasation from intravenous (IV) anthracyclines such as doxorubicin ( Adriamycin , and others). Dexrazoxane has been available…

Med Lett Drugs Ther. 2007 Dec 3; 49(1275):100
The FDA has approved a new formulation of dexrazoxane (Totect) for treatment of extravasation from intravenous (IV) anthracyclines such as doxorubicin ( Adriamycin , and others). Dexrazoxane has been available since 1995 as Zinecard for protection against the cardiac toxicity of anthracyclines (Med Lett Drugs Ther 1995; 37:110) . It is also available generically. The drug’s precise mechanism of action is not known, but anthracyclines are vesicants that bind to DNA and act as oxidizing agents in the presence of iron. Dexrazoxane is a topoisomerase inhibitor, possibly interfering with anthracycline effects on DNA, and is also a potent iron-chelating agent, preventing free-radical formation. In uncontrolled clinical trials, dexrazoxane appears to have prevented severe necrosis that would require surgical debridement (HT Mouridsen et al. Ann Oncol 2007; 18:546. epub) . It is given in a dose of 1000 mg/m 2 (2000 mg maximum) as an IV infusion over 1-2 hours as soon as possible (no later than 6 hours) after extravasation has occurred and again 24 hours later, and then in a dose of 500 mg/m 2 (1000 mg maximum) 48 hours after the first dose. The dose should be reduced by half in patients with a creatinine clearance <40 mL/min. Download U.S. English
Issue 48 · August 1, 2006
Chemotherapy for Esophageal, Gastric and Colorectal Cancers

A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and…

Treat Guidel Med Lett. 2006 Aug; 4(48):55-60
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Issue 1229 · February 27, 2006
Coenzyme Q10

Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.

Med Lett Drugs Ther. 2006 Feb 27; 48(1229):19-20
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.
Issue 1201 · January 31, 2005
Azacitidine (Vidaza) for Myelodysplastic Syndrome

Azacitidine ( Vidaza - Pharmion), a pyrimidine nucleoside analog of cytidine, is the first drug approved by the FDA for treatment of myelodysplastic syndrome (MDS). Azacitidine is incorporated into newly…

Med Lett Drugs Ther. 2005 Jan 31; 47(1201):11
Azacitidine ( Vidaza - Pharmion), a pyrimidine nucleoside analog of cytidine, is the first drug approved by the FDA for treatment of myelodysplastic syndrome (MDS). Azacitidine is incorporated into newly synthesized DNA and inhibits DNA methyltransferase. Hypomethylation of DNA can restore the normal expression of genes critical for cell differentiation.
Issue 29 · January 1, 2005
Drugs for Breast Cancer

In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for…

Treat Guidel Med Lett. 2005 Jan; 3(29):1-6
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Issue 1179 · March 29, 2004
Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Palonosetron ( Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT 3 ) receptor antagonist to become available in the US and the first to be approved…

Med Lett Drugs Ther. 2004 Mar 29; 46(1179):27-8
Palonosetron ( Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT 3 ) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin ( Platinol , and others). Aprepitant ( Emend ), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT 3 antagonist and dexamethasone to prevent both acute and delayed nausea and vomiting due to highly emetogenic drugs ( Medical Letter 2003; 45:62 ).
Issue 1162 · August 4, 2003
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 )…

Med Lett Drugs Ther. 2003 Aug 4; 45(1162):62-3
Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 ) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin.
Issue 1161 · July 21, 2003
Bortezomib (Velcade) for Multiple Myeloma

Bortezomib (PS341; Velcade Millenium), the first proteasome inhibitor, has received accelerated approval from the FDA for treatment of refractory multiple myeloma. This review includes descriptions of the…

Med Lett Drugs Ther. 2003 Jul 21; 45(1161):57-68
Bortezomib (PS341; Velcade Millenium), the first proteasome inhibitor, has received accelerated approval from the FDA for treatment of refractory multiple myeloma. This review includes descriptions of the mechanism of action, pharmacokinetics, adverse effects, and dosage and cost of bortezomib, outlines the results of clinical studies, and concludes with an overall assessment of the drug's effectiveness.
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 7 · March 1, 2003
Drugs of Choice for Cancer

The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants.…

Treat Guidel Med Lett. 2003 Mar; 1(7):41-52
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer drugs and their adverse effects are listed in Table II on page 46. A partial list of brand names appears on page 52.
Issue 1087 · September 18, 2000
Drugs of Choice For Cancer Chemotherapy (combined issue 1087-1088)

The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for…

Med Lett Drugs Ther. 2000 Sep 18; 42(1087):83-92
The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. For many of the cancers listed, surgery and/or radiation therapy are also part of the management of the disease.
Issue 1071 · February 7, 2000
Epirubicin for Adjuvant Therapy in Node-Positive Breast Cancer

Epirubicin, an analog of doxorubicin that has been available in Europe and Canada for 15 years, has now been approved by the FDA for adjuvant use after resection of the primary tumor in breast cancer patients…

Med Lett Drugs Ther. 2000 Feb 7; 42(1071):12-3
Epirubicin, an analog of doxorubicin that has been available in Europe and Canada for 15 years, has now been approved by the FDA for adjuvant use after resection of the primary tumor in breast cancer patients with axillary node involvement.
Issue 1049 · March 26, 1999
Valrubicin for Bladder Cancer

Valrubicin (Valstar), formerly known as AD 32, has been approved by the FDA for intravesical treament of bladder cancer. The approval is limited to patients with carcinoma-in-situ refractory to BCG for whom…

Med Lett Drugs Ther. 1999 Mar 26; 41(1049):32
Valrubicin (Valstar), formerly known as AD 32, has been approved by the FDA for intravesical treament of bladder cancer. The approval is limited to patients with carcinoma-in-situ refractory to BCG for whom immediate cystectomy is contraindicated.
Issue 1039 · November 6, 1998
Capecitabine and Trastuzumab for Metastatic Breast Cancer

Trastuzumab ( Herceptin - Genentech), a recombinant 'humanized' monoclonal antibody (rhuMAb) that binds to a protein encoded by the oncogene HER2, and capecitabine (ka pe site' a been; Xeloda - Roche), an oral…

Med Lett Drugs Ther. 1998 Nov 6; 40(1039):106-8
Trastuzumab ( Herceptin - Genentech), a recombinant 'humanized' monoclonal antibody (rhuMAb) that binds to a protein encoded by the oncogene HER2, and capecitabine (ka pe site' a been; Xeloda - Roche), an oral pro-drug for 5-fluorouracil, have been approved by the FDA for treatment of metastatic breast cancer.
Issue 1032 · July 31, 1998
Recombinant Interleukin-11 for Chemotherapy-Induced Thrombocytopenia

The US Food and Drug Administration (FDA) has approved use of recombinant human interleukin 11 (rhIL-11; oprelvekin; Neumega - Genetics Institute) to increase platelet counts and decrease the need for platelet…

Med Lett Drugs Ther. 1998 Jul 31; 40(1032):75-7
The US Food and Drug Administration (FDA) has approved use of recombinant human interleukin 11 (rhIL-11; oprelvekin; Neumega - Genetics Institute) to increase platelet counts and decrease the need for platelet transfusions in patients with severe thrombocytopenia caused by chemotherapy for nonmyeloid malignancies.
Issue 1029 · June 19, 1998
Rituximab for Non-Hodgkins Lymphoma

Rituximab ( Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas.

Med Lett Drugs Ther. 1998 Jun 19; 40(1029):65-6
Rituximab ( Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas.
Issue 984 · September 27, 1996
Docetaxel (Taxotere) for Advanced Breast Cancer

Docetaxel ( Taxotere - Rh ne-Poulenc Rorer), a semisynthetic taxoid similar to paclitaxel ( Taxol - Medical Letter, 35:39, 1993), has been approved by the US Food and Drug Administration for use in locally…

Med Lett Drugs Ther. 1996 Sep 27; 38(984):87-8
Docetaxel ( Taxotere - Rh ne-Poulenc Rorer), a semisynthetic taxoid similar to paclitaxel ( Taxol - Medical Letter, 35:39, 1993), has been approved by the US Food and Drug Administration for use in locally advanced or metastatic breast cancer that has progressed or relapsed during treatment that included an anthracycline such as doxorubicin ( Adriamycin , and others).
Issue 944 · March 17, 1995
Pegaspargase for Acute Lymphoblastic Leukemia

Pegaspargase (peg as par jase; PEG-L-asparaginase; Oncaspar - Rh ne-Poulenc Rorer), a polyethylene glycol (PEG) conjugate of L-asparaginase, has been approved by the US Food and Drug Administration for…

Med Lett Drugs Ther. 1995 Mar 17; 37(944):23-4
Pegaspargase (peg as par jase; PEG-L-asparaginase; Oncaspar - Rh ne-Poulenc Rorer), a polyethylene glycol (PEG) conjugate of L-asparaginase, has been approved by the US Food and Drug Administration for treatment of acute lymphoblastic leukemia (ALL), the most common malignancy of childhood. The new drug is recommended only for patients who have had allergic reactions to asparaginase. Asparaginase is available commercially as Elspar, which is derived from Escherichia coli. A formulation derived from Erwinia chrysanthemi is available on an investigational basis (Ogden Bioservices, 301-762-0069). Some patients who have had allergic reactions to E. coli asparaginase can tolerate Erwinia asparaginase.
Issue 912 · December 24, 1993
Drugs for Vomiting Caused by Cancer Chemotherapy

Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.

Med Lett Drugs Ther. 1993 Dec 24; 35(912):124-6
Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.
Issue 883 · November 13, 1992
Teniposide for Acute Lymphoblastic Leukemia

Teniposide (ten i poe' side; VM 26; Vumon - Bristol), an anticancer drug that has been under investigation in the USA for 20 years, has now been approved for use in combination induction treatment of…

Med Lett Drugs Ther. 1992 Nov 13; 34(883):105-6
Teniposide (ten i poe' side; VM 26; Vumon - Bristol), an anticancer drug that has been under investigation in the USA for 20 years, has now been approved for use in combination induction treatment of refractory acute lymphoblastic leukemia (ALL) in children. A semisynthetic derivative of podophyllotoxin, teniposide is chemically related to etoposide ( VePesid - Medical Letter, 26:48, 1984).
Issue 852 · September 6, 1991
Idarubicin

Idarubicin hydrochloride ( Idamycin - Adria), an anthracycline structurally related to daunorubicin ( Cerubidine , and others) and doxorubicin ( Adriamycin , and others), was recently approved in the USA for…

Med Lett Drugs Ther. 1991 Sep 6; 33(852):84-5
Idarubicin hydrochloride ( Idamycin - Adria), an anthracycline structurally related to daunorubicin ( Cerubidine , and others) and doxorubicin ( Adriamycin , and others), was recently approved in the USA for treatment of acute myelogenous leukemia (AML) in adults.
Issue 852 · September 6, 1991
A Drug Prevention of Anthracycline-Induced Cardiac Toxicity

Recent studies have caused concern about cardiomyopathy associated with doxorubicin ( Adriamycin , and others), daunorubicin ( Cerubidine , and others), idarubicin ( Idamycin ), mitoxantrone ( Novantrone ),…

Med Lett Drugs Ther. 1991 Sep 6; 33(852):85-6
Recent studies have caused concern about cardiomyopathy associated with doxorubicin ( Adriamycin , and others), daunorubicin ( Cerubidine , and others), idarubicin ( Idamycin ), mitoxantrone ( Novantrone ), and related anthracycline or anthraquinone anticancer drugs. Dexrazoxane (ADR-529, ICRF-187 - Adria), a piperazine derivative of ethylenediaminetetraacetic acid (EDTA), is now under investigation for prevention of this drug-induced cardiomyopathy.
Issue 850 · August 9, 1991
Altretamine For Ovarian Cancer

Altretamine ( Hexalen - US Bioscience; Hexastat - Rh ne-Poulenc in Canada), formerly known only by its chemical name, hexamethylmelamine, was recently approved by the US Food and Drug Administration as a…

Med Lett Drugs Ther. 1991 Aug 9; 33(850):76-7
Altretamine ( Hexalen - US Bioscience; Hexastat - Rh ne-Poulenc in Canada), formerly known only by its chemical name, hexamethylmelamine, was recently approved by the US Food and Drug Administration as a single agent for palliative oral treatment of persistent or recurrent ovarian cancer.
Issue 847 · June 28, 1991
Granulocyte Colony-Stimulating Factors

The US Food and Drug Administration recently approved the marketing of G-CSF (recombinant human granulocyte colony-stimulating factor, generic name filgrastim, Neupogen - Amgen) and GM-CSF (recombinant human…

Med Lett Drugs Ther. 1991 Jun 28; 33(847):61-3
The US Food and Drug Administration recently approved the marketing of G-CSF (recombinant human granulocyte colony-stimulating factor, generic name filgrastim, Neupogen - Amgen) and GM-CSF (recombinant human granulocyte-macrophage colony-stimulating factor, generic name sargramostim, Leukine - Immunex, Prokine - Hoechst-Roussel). G-CSF is approved for use after cancer chemotherapy in patients with non-myeloid malignancies to decrease the incidence of infection. GM-CSF is approved for acceleration of myeloid recovery after autologous bone marrow transplantation in non-Hodgkin's lymphoma, Hodgkin's disease, and acute lymphoblastic leukemia.
Issue 847 · June 28, 1991
Ondansentron To Prevent Vomiting After Cancer Chemotherapy

Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An…

Med Lett Drugs Ther. 1991 Jun 28; 33(847):63-4
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An oral formulation is available in many other countries.
Issue 841 · April 5, 1991
BCG For Bladder Cancer

BCG Live ( TheraCys - Connaught) and BCG Vaccine U.S.P. ( TiceBCG - Organon), freeze-dried suspensions of an attenuated strain of Mycobacterium bovis , were recently approved by the US Food and Drug…

Med Lett Drugs Ther. 1991 Apr 5; 33(841):29-30
BCG Live ( TheraCys - Connaught) and BCG Vaccine U.S.P. ( TiceBCG - Organon), freeze-dried suspensions of an attenuated strain of Mycobacterium bovis , were recently approved by the US Food and Drug Administration for intravesical treatment of primary or relapsed carcinoma in situ of the bladder, with or without associated papillary tumors. BCG is not recommended for treatment of papillary tumors occurring alone.
Issue 818 · May 18, 1990
Adjuvant Chemotherapy of Early Breast Cancer

The most important prognostic variable in early breast cancer is axillary lymph node involvement. Based on past experience, after 10 years about 70% of node-negative patients will be alive and apparently free…

Med Lett Drugs Ther. 1990 May 18; 32(818):49-50
The most important prognostic variable in early breast cancer is axillary lymph node involvement. Based on past experience, after 10 years about 70% of node-negative patients will be alive and apparently free of disease; about 30% will have relapsed or died. Patients with positive nodes may have a 30% to 60% relapse rate, depending on the number of positive nodes and other prognostic factors, such as the presence of estrogen receptors (IC Henderson et al, in VT DeVita, Jr et al, eds, Cancer: Principles and Practice of Oncology, 3rd ed, Philadelphia:Lippincott, 1989, p 1197). Which of these patients should receive adjuvant treatment with cytotoxic drugs and/or endocrine therapy is controversial; a National Cancer Institute (NCI) Consensus Conference on this subject is scheduled for June.
Issue 769 · July 1, 1988
Mitoxantrone

Mitoxantrone ( Novantrone - Lederle), a synthetic anthracene related to the anthracyclines doxorubicin ( Adriamycin ) and daunorubicin ( Cerubidine ), has now been marketed in the USA to be used in combination…

Med Lett Drugs Ther. 1988 Jul 1; 30(769):67-8
Mitoxantrone ( Novantrone - Lederle), a synthetic anthracene related to the anthracyclines doxorubicin ( Adriamycin ) and daunorubicin ( Cerubidine ), has now been marketed in the USA to be used in combination with other drugs for initial treatment of acute nonlymphocytic leukemia in adults.
Issue 756 · January 1, 1988
Nabilone And Other Antiemetic For Cancer Patients

Nabilone ( Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and…

Med Lett Drugs Ther. 1988 Jan 1; 30(756):2-4
Nabilone ( Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and vomiting associated with cancer chemotherapy. Oral THC itself, known generically as dronabinol ( Marinol ), is also commercially available as an antiemetic for cancer patients (Medical Letter, 27:97, 1985). Other drugs used for this purpose include metoclopramide ( Reglan - Medical Letter, 24:67, 1982), prochlorperazine ( Compazine ; and others), haloperidol ( Haldol ; and others), and corticosteroids. Benzodiazepines, such as lorazepam ( Ativan ; and others), are used to treat anticipatory nausea and vomiting that occurs before chemotherapy begins.